Bergen, Norway, 23 April 2019 - The board of directors in BerGenBio ASA (the "Company") (OSE:BGBIO) has granted options to primary insiders.
The annual general meeting in the Company at 13 March 2019 approved the share options program. Options granted under the option program is vested over a three-year period and each option, when exercised, will give the right to acquire one share in the Company.
A total of 784,629 share options were granted at an exercise price at NOK 25.00, of this the following was granted to primary insiders (total holdings of share options following this grant):
Richard Godfrey - CEO: 236,800 (1,354,284)
Rune Skeie - CFO: 52,000 (96,090)
Dominic Smethurst – CMO: 110,000 (110,000)
James B. Lorens – Senior Scientific Advisor: 20,800 (738,507)
James Barnes, Director of regulatory Affairs and Programme Management: 59,400 (59,400)
Gro Gausdal, Director of research: 11,880 (91,709)
Tone Bjaaland - Director of Clinical operations: 18,513 (63,513)
Endre Kjærland - Associate Director of IP and Contracts: 8,300 (103,525)
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
ir@bergenbio.com
+47 917 86 304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.